Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Apr 7;23(1):135.
doi: 10.1186/s12882-022-02769-9.

IgA nephropathy relapse following COVID-19 vaccination treated with corticosteroid therapy: case report

Affiliations
Case Reports

IgA nephropathy relapse following COVID-19 vaccination treated with corticosteroid therapy: case report

Shota Watanabe et al. BMC Nephrol. .

Abstract

Background: The flare of immune-mediated disease following coronavirus disease of 2019 (COVID-19) vaccination is a rare adverse event following immunization. De novo, as well as relapsing IgA nephropathy (IgAN) cases, have been reported following either mRNA-1273 (Moderna) or BNT162b2 (Pfizer-BioNTech) vaccination. To our knowledge, the majority of IgAN relapses did not result in severe acute kidney injury (AKI) and resolved spontaneously.

Case presentation: This is a case of a 54-year-old female with a previous diagnosis of IgAN who developed IgAN relapse following the second dose of Moderna vaccine. Gross hematuria developed 2 days after vaccination, which was accompanied by significant AKI. Kidney biopsy showed mild tubular atrophy and IgA staining in mesangium without crescent formation. Significant improvement in serum creatinine (Cr) was observed on day 10 after initiating prednisone. Cr came back to normal within 3 months after initiating corticosteroid.

Conclusion: COVID-19 vaccination is associated with a flare of IgAN that may cause significant AKI. Steroid therapy is associated with recovery. IgAN flare after COVID-19 vaccination should be closely monitored to elucidate any adverse effect associated with the novel vaccine.

Keywords: AKI; COVID-19 vaccine; Hematuria; IgA nephropathy; Kidney biopsy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Histopathologic findings from renal biopsy. a Light microscopy shows no mesangial or endocapillary hypercellularity, or crescents. Fibrous adhesion to the Bowman capsule is identified focally (black arrow). There is mild interstitial fibrosis and tubular atrophy (original magnification × 10). b Immunofluorescence analysis demonstrates weak IgA staining in mesangium (original magnification × 20). c Immunofluorescence analysis demonstrates negative IgG staining in mesangium (original magnification × 20). d Electron microscopy reveals a small number of mesangial electron-dense deposits, especially underneath paramesangial basement membranes (white arrow). Bar = 1 μm

References

    1. Watad A, De Marco G, Mahajna H, Druyan A, Eltity M, Hijazi N, et al. Immune-mediated disease flares or new-onset disease in 27 subjects following mrna/dna sars-cov-2 vaccination. Vaccines. 2021;9:1–23. doi: 10.3390/vaccines9050435. - DOI - PMC - PubMed
    1. Lavery MJ, Nawimana S, Parslew R, Stewart L. A flare of pre-existing erythema multiforme following BNT162b2 (Pfizer–BioNTech) COVID-19 vaccine. Clin Exp Dermatol. 2021;46:0–2. - PMC - PubMed
    1. Toom S, Wolf B, Avula A, Peeke S, Becker K. Familial thrombocytopenia flare-up following the first dose of mRNA-1273 Covid-19 vaccine. Am J Hematol. 2021;96:E134–E135. doi: 10.1002/ajh.26128. - DOI - PMC - PubMed
    1. Cohen SR, Prussick L, Kahn JS, Gao DX, Radfar A, Rosmarin D. Leukocytoclastic vasculitis flare following the COVID-19 vaccine. Int J Dermatol. 2021;60:1032–1033. doi: 10.1111/ijd.15623. - DOI - PMC - PubMed
    1. Negrea L, Rovin BH. Gross hematuria following vaccination for severe acute respiratory syndrome coronavirus 2 in 2 patients with IgA nephropathy. Kidney Int. 2021;99:1487. doi: 10.1016/j.kint.2021.03.002. - DOI - PMC - PubMed

Publication types